Contextual tumor suppressor function of T cell death-associated gene 8 (TDAG8) in hematological malignancies

Table 2 Reduced TDAG8 gene expression correlates with resistance to various chemotherapeutics

Drug	Elesclomol (leukemia)	Panobinostat (multi-cancer)	Irinotecan (multi-cancer)	Topotecan (multi-cancer)	Navitoclax (leukemia)	MK2206 (leukemia)
Mechanism of action	Unknown oxidative Stress	Histone deacetylase inhibitor	Topoisomerase inhibitor	Topoisomerase inhibitor	Bcl-2, Bcl-XL, and Bcl-w inhibitor	AKT inhibitor
Resistant cell lines (Rn)	21	164	84	124	12	17
Sensitive cell lines (Sn)	4	86	71	154	6	3
TDAG8 gene expression of Sn vs Rn	+ 2.3	+ 2.7	+ 3.2	+ 2.2	+ 2.4	+ 3.8
P	4.8E⁻²	2.6E⁻⁷	4.2E⁻⁸	2.9E⁻¹⁰	3.4E⁻²	7.8E⁻⁴

Cancer cells of various origins categorized as resistant to specific chemotherapeutics demonstrate a significant reduction in TDAG8 gene expression. The expression of TDAG8 in 4 cell lines sensitive to elesclomol is 2.3-fold higher than in 21 cell lines resistant. The expression of TDAG8 in 86 cell lines categorized as sensitive to panobinostat is 2.7-fold higher than in 164 cell lines categorized as resistant. The expression of TDAG8 in 71 cell lines categorized as sensitive to irinotecan is 3.2-fold higher than in 84 cell lines categorized as resistant. The expression of TDAG8 in 154 cell lines categorized as sensitive to topotecan is 2.2-fold higher than in 124 cell lines categorized as resistant. The expression of TDAG8 in 6 cell lines categorized as sensitive to navitoclax is 2.4-fold higher than in 12 cell lines categorized as resistant. The expression of TDAG8 in 3 cell lines categorized as sensitive to MK2206 is 3.8-fold higher than in 17 cell lines categorized as resistant

ISSN: 1479-5876